Full Breakdown
Market Movements as 2025 Closes: A Look at Key Stocks
1/2/2026, 11:28:01 AM
Overview of Market Performance
As 2025 concluded, U.S. stock markets experienced a downturn on December 31, with major indices like the S&P 500 and Nasdaq falling by 0.74% and 0.76%, respectively. This decline was observed amid thin trading conditions typical of the holiday season, leading investors to reassess their positions as they prepared for the new year.
3M Company: Earnings Outlook and Legal Liabilities
3M Co shares closed at $160.10, down 0.7% on the final trading day of 2025. Despite this dip, the stock had risen approximately 25% over the year. Investors are now focused on 3M's earnings guidance for 2026, particularly after the company raised its adjusted profit forecast in October, driven by tighter cost controls and a shift towards higher-margin products. Legal liabilities, particularly a $10.3 billion pre-tax accrual related to PFAS settlements, remain a significant factor in the company's valuation. The next earnings report is anticipated on January 27, 2026, where investors will seek clarity on earnings per share and updates on organic sales.
Symbotic Inc: Growth Expectations Amid Valuation Concerns
Symbotic shares ended 2025 at $59.50, down 1.28%. The company, which specializes in automation for distribution centers, is closely watched for its quarterly updates and customer growth, particularly with Walmart, which accounted for 85% of its revenue. Analysts forecast revenue of approximately $622.3 million for the upcoming quarter, but the stock's high price-to-earnings ratio of around 150 raises concerns about its valuation. The next earnings report is also expected in late January.
Merck & Co.: Navigating Patent Challenges
Merck shares closed at $105.26, down 0.75%. The company faces a critical period as it approaches a patent cliff for its leading cancer drug, Keytruda. Investors are keenly awaiting the upcoming JPMorgan Healthcare Conference from January 12-15 and Merck's earnings report on February 3, where they will look for insights into new growth strategies and product pipeline developments to offset potential revenue declines from Keytruda.
AbbVie Inc: Defensive Strategies in a Changing Market
AbbVie shares finished at $228.49, down 0.5%. The company is navigating the competitive landscape following the introduction of biosimilars to its former blockbuster drug, Humira. AbbVie is focusing on newer immunology products and is set to pay a quarterly dividend on February 17, 2026. Investors will be monitoring the stock's performance against its 52-week high of $244.81 and its upcoming earnings report for guidance on its transition strategy.
AST SpaceMobile: Execution Risks and Future Launches
AST SpaceMobile shares closed at $72.63, down 2.8%. The company has seen significant volatility as it works towards launching a network of satellites that connect directly to smartphones. Following a strong performance in 2025, investors are now focused on execution risks related to launch schedules and cash management. The next earnings update is scheduled for March 2, 2026, where performance metrics will be scrutinized.
Conclusion: Looking Ahead
As markets reopen in 2026, investors will be closely watching macroeconomic indicators, including the U.S. employment report on January 9 and the Consumer Price Index on January 13. The Federal Reserve's policy meeting on January 27-28 will also be pivotal in shaping market sentiment. The performance of key stocks like 3M, Symbotic, Merck, AbbVie, and AST SpaceMobile will be critical as they navigate their respective challenges and opportunities in the new year.
